Do analysts recommend COCP or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 594.44%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is COCP or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Lexaria Bioscience N/A -174.93% -143.89%

Is QNTM or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -582.23% -184.20% Lexaria Bioscience N/A -174.93% -143.89%

Is CLRB or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts rate BFRI or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 594.44%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Lexaria Bioscience (LEXX) Competitors

$3.24 -0.05 (-1.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.10 -0.14 (-4.32%)

As of 09/18/2026 07:51 PM Eastern

Compare

LEXX vs. COCP, QNTM, CLRB, AYTU, and BFRI

Should you buy Lexaria Bioscience stock or one of its competitors? Lexaria Bioscience's main competitors and comparable companies include Cocrystal Pharma (COCP), Quantum Biopharma (QNTM), Cellectar Biosciences (CLRB), Aytu BioPharma (AYTU), and Biofrontera (BFRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lexaria Bioscience compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 594.44%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cocrystal Pharma's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience's return on equity of -174.93% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Cocrystal Pharma has higher earnings, but lower revenue than Lexaria Bioscience. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Lexaria Bioscience	$710K	7.53	-$11.90M	-$5.10	N/A

Cocrystal Pharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Lexaria Bioscience beats Cocrystal Pharma on 7 of the 12 factors compared between the two stocks.

How does Lexaria Bioscience compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

In the previous week, Quantum Biopharma had 6 more articles in the media than Lexaria Bioscience. MarketBeat recorded 6 mentions for Quantum Biopharma and 0 mentions for Lexaria Bioscience. Quantum Biopharma's average media sentiment score of 0.30 beat Lexaria Bioscience's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience's return on equity of -174.93% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-582.23%	-184.20%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has higher revenue and earnings than Quantum Biopharma. Quantum Biopharma is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A
Lexaria Bioscience	$710K	7.53	-$11.90M	-$5.10	N/A

Quantum Biopharma currently has a consensus target price of $8.00, indicating a potential upside of 118.58%. Lexaria Bioscience has a consensus target price of $22.50, indicating a potential upside of 594.44%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quantum Biopharma has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lexaria Bioscience beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Lexaria Bioscience compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Lexaria Bioscience has higher revenue and earnings than Cellectar Biosciences. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Lexaria Bioscience	$710K	7.53	-$11.90M	-$5.10	N/A

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cellectar Biosciences' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience's return on equity of -174.93% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 362.18%. Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 594.44%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cellectar Biosciences has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Cellectar Biosciences beats Lexaria Bioscience on 8 of the 13 factors compared between the two stocks.

How does Lexaria Bioscience compare to Aytu BioPharma?

Lexaria Bioscience (NASDAQ:LEXX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lexaria Bioscience has higher earnings, but lower revenue than Aytu BioPharma. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	7.53	-$11.90M	-$5.10	N/A
Aytu BioPharma	$66.38M	0.34	-$13.56M	-$4.58	N/A

In the previous week, Lexaria Bioscience's average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Aytu BioPharma	Neutral

Lexaria Bioscience has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Lexaria Bioscience currently has a consensus price target of $22.50, indicating a potential upside of 594.44%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 407.08%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lexaria Bioscience has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

Aytu BioPharma beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks.

How does Lexaria Bioscience compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 594.44%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Lexaria Bioscience has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Biofrontera has higher revenue and earnings than Lexaria Bioscience. Biofrontera is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A
Lexaria Bioscience	$710K	7.53	-$11.90M	-$5.10	N/A

In the previous week, Biofrontera had 5 more articles in the media than Lexaria Bioscience. MarketBeat recorded 5 mentions for Biofrontera and 0 mentions for Lexaria Bioscience. Biofrontera's average media sentiment score of 0.66 beat Lexaria Bioscience's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Lexaria Bioscience	Neutral

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biofrontera beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.35M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.64	792.21	274.93	25.38
Price / Sales	7.53	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	1.62	10.53	10.46	6.33
Net Income	-$11.90M	$2.82B	$3.49B	$358.33M
7 Day Performance	-18.39%	1.69%	0.59%	1.12%
1 Month Performance	-71.25%	0.24%	-1.74%	-2.39%
1 Year Performance	-82.58%	3.95%	18.13%	5.35%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	1.4599 of 5 stars	$3.24 -1.5%	$22.50 +594.4%	-82.6%	$5.35M	$710K	N/A	7	Analyst Upgrade
COCP Cocrystal Pharma	0.8079 of 5 stars	$1.14 -2.6%	N/A	-11.0%	$22.54M	N/A	N/A	10	Gap Up
QNTM Quantum Biopharma	2.6274 of 5 stars	$3.46 flat	$8.00 +131.2%	-80.6%	$22.14M	N/A	N/A	N/A	News Coverage
CLRB Cellectar Biosciences	1.7222 of 5 stars	$2.32 +0.4%	$11.00 +374.1%	-54.2%	$21.83M	N/A	N/A	10
AYTU Aytu BioPharma	1.649 of 5 stars	$1.99 -0.5%	$10.75 +440.2%	-13.1%	$21.47M	$66.38M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. COCP, QNTM, CLRB, AYTU, and BFRI

How does Lexaria Bioscience compare to Cocrystal Pharma?

Summary

How does Lexaria Bioscience compare to Quantum Biopharma?

Summary

How does Lexaria Bioscience compare to Cellectar Biosciences?

Summary

How does Lexaria Bioscience compare to Aytu BioPharma?

Summary

How does Lexaria Bioscience compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. COCP, QNTM, CLRB, AYTU, and BFRI

How does Lexaria Bioscience compare to Cocrystal Pharma?

Do analysts recommend COCP or LEXX?

Do institutionals & insiders have more ownership in COCP or LEXX?

Does the media favor COCP or LEXX?

Is COCP or LEXX more profitable?

Which has preferable earnings and valuation, COCP or LEXX?

Which has more volatility & risk, COCP or LEXX?

Summary

How does Lexaria Bioscience compare to Quantum Biopharma?

Does the media prefer QNTM or LEXX?

Is QNTM or LEXX more profitable?

Which has higher valuation & earnings, QNTM or LEXX?

Do analysts rate QNTM or LEXX?

Which has more volatility and risk, QNTM or LEXX?

Do insiders & institutionals have more ownership in QNTM or LEXX?

Summary

How does Lexaria Bioscience compare to Cellectar Biosciences?

Which has better valuation and earnings, CLRB or LEXX?

Do insiders & institutionals hold more shares of CLRB or LEXX?

Does the media favor CLRB or LEXX?

Is CLRB or LEXX more profitable?

Do analysts recommend CLRB or LEXX?

Which has more volatility & risk, CLRB or LEXX?

Summary

How does Lexaria Bioscience compare to Aytu BioPharma?

Do insiders and institutionals believe in LEXX or AYTU?

Which has stronger valuation & earnings, LEXX or AYTU?

Does the media refer more to LEXX or AYTU?

Which has more volatility & risk, LEXX or AYTU?

Do analysts rate LEXX or AYTU?

Is LEXX or AYTU more profitable?

Summary

How does Lexaria Bioscience compare to Biofrontera?

Do analysts rate BFRI or LEXX?

Which has more volatility and risk, BFRI or LEXX?

Is BFRI or LEXX more profitable?

Which has higher valuation & earnings, BFRI or LEXX?

Does the media refer more to BFRI or LEXX?

Do insiders & institutionals have more ownership in BFRI or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools